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Abstract
The assessment of drug-target engagement for determining the efficacy of a compound inside cells
remains challenging, particularly for difficult target proteins. Existing techniques aremore suited to
soluble protein targets. Difficult target proteins include thosewith challenging in vitro solubility,
stability or purification properties that preclude target isolation.Here, we report a novel technique
thatmeasures intracellular compound-target complex formation, aswell as cellular permeability,
specificity and cytotoxicity-the toxicity-affinity-permeability-selectivity (TAPS) technique. The TAPS
assay is exemplified here using human kynurenine 3-monooxygenase (KMO), a challenging
intracellularmembrane protein target of significant current interest. TAPS confirmed target binding
of knownKMO inhibitors inside cells.We conclude that the TAPS assay can be used to facilitate
intracellular hit validation onmost, if not all intracellular drug targets.
Introduction
The efficacy of a drug relies upon interaction with a
relevant therapeutic target protein at the physiological
site of activity. Direct detection of this interaction
in vitro remains a challenge, particularly if isolated
protein cannot be obtained or if a suitable assay
method cannot be designed. The measurement of
binding of a hit, lead or drug to its intended target is
particularly challenging in cells. Therefore, detection
of target engagement is one of the major challenges in
hit validation from phenotypic assays [1–3]. Several
methods have been reported for detection of drug-
target engagement. A selection of creative techniques
which utilise functionalised drugs or probes with
fluorescence polarised imaging have recently been
described [4–7]. Others use chemoproteomicmethods
to profile the spectrum of proteins interacting with
chemical probes [8]. Such techniques require specia-
lised/adapted instruments and/or capacity for pro-
duction of fluorescently labelled probes. The current
standard for demonstrating intracellular target
engagement is the cellular thermal shift assay
(CETSA), which detects ligand-induced thermal stabi-
lisation of target proteins [9–11]. However, the
authors state that the method is ‘not likely to work for
highly inhomogeneous proteins’. In general, challen-
ging drug targets which are not readily expressed in a
soluble form, which are unstable in solution or which
behave differently in the absence of key co-factors or
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protein binding partners pose difficulties. We devel-
oped the TAPS method to provide a solution for this
gap in target engagement measurement and to extend
the toolbox of approaches for soluble protein targets.
TAPS combines fluorescence activated cell sorting
(FACS) with liquid chromatography mass spectro-
metry (LC-MS/MS) analysis to detect binding of drugs
to their target inside cells in a concentration-depen-
dent manner producing results which resemble an
apparent binding curve of a small molecule to a target
in any cellular context. Additionally, TAPS selects, in a
single assay method, compounds with sufficient
cellular permeability, and excludes, via necessary
controls, compounds which lack specificity or demon-
strate high cytotoxicity. This method is generally
applicable for any intracellular target which can be
expressed as a fluorescent fusion protein and its
applicability to challenging membrane proteins is
demonstrated here.
The TAPS technique involves transient expression
of the gene of interest as a fluorescent protein con-
jugate in an appropriate cell type to generate a range of
target concentrations. Thus, fluorescently tagged tar-
get proteins are assayed in a cellular environment in
the presence of endogenous co-factors and protein–
protein interactors in a physiologically relevant tissue.
The protein is produced within 24 h and the trans-
fected cells are incubated with single or pooled com-
pounds. Cells are subjected to FACS analysis and
sorted according to fluorescence intensity exhibited by
the fluorescent fusion protein. Lysis of the sorted
populations is followed by LC-MS/MS analysis,
allowing comparison of compounds bound in target-
free non-transfected cells and those bound in the
fluorescently intense cells expressing varying levels of
the target protein. Negative cells resulting from tran-
sient expression in these experiments act as an impor-
tant integral control allowing the specificity of drug
binding to be determined. In cases where it is not pos-
sible to transiently express a target protein of interest,
stably transfected cell lines can be utilised in parallel
with the native non-transfected cell line to perform the
TAPS assay.
The TAPS assay was developed using the mito-
chondrial membrane associated enzyme kynurenine
3-monooxygenase (KMO). This enzyme is emerging
as an increasingly important target for drug develop-
ment since it has recently been implicated as a ther-
apeutic target for Huntington’s disease [12] and
multiple organ failure caused by severe acute pancrea-
titis [13]. However, human KMO is difficult to pro-
duce and isolate in a recombinant form since it is
membrane-associated and requires the presence of a
lipid and proteinaceous environment to maintain
activity. The hydrophobic membrane-targeting
domain at the C-terminus of this NADPH-dependant
flavoprotein hydroxylase is believed to be responsible
for its low aqueous solubility, poor stability, and ten-
dency to aggregate with other membrane proteins
when expressed recombinantly [14–16]. Therefore,
the importance of assaying drug-KMO engagement
directly in mammalian cells in the presence of co-fac-
tors and intracellular binding proteins required for
enzyme functionality was paramount. Development
and successful application of the TAPS method for
assaying compounds against KMO inside cells pro-
vides a strong indication that this technique is applic-
able for targeting other challenging proteins.
Materials andmethods
Cloning
The E2-Crimson-human KMO gene (Cys452 variant)
was synthesised by GenScript in vector pUC57. The
DNA sequence for E2-crimson was sourced from
Clontech. The gene for the fluorescent-KMO fusion
was ligated into vector pCDNA3.1 (Invitrogen) using
restriction sites NheI (N-terminus) and NotI (C-
terminus).
Transient expression offluorescent target protein
HEK293 cells were passaged in poly-D-Lysine treated
plates and incubated overnight in OPTI-MEM med-
ium (Lonza) at 37 °C, 5% CO2. The cells were
transiently transfected the following day with
pcDNA3.1-E2-Crimson-huKMODNAusing Lipofec-
tamine 2000 (Invitrogen) in OPTI-MEM medium by
standard transfection protocol. Transfection medium
was removed from the cells 6 h post-transfection and
replaced with DMEM containing 10% FBS, 1%
L-glutamine and 1% penicillin-streptomycin (Life
Technologies). The transfected cells were maintained
at 37 °C, 5%CO2 for 24–48 h post-transfection before
the TAPS assay was performed. Transfection of the
cells and the subsequent assay were performed in a
variety of plate formats (6-, 12-, 24- and 48-well)
during development of the assay, compound screening
was performed in 6-well plate format.
TAPS assay
Step 1: Compound incubation
Compounds were diluted to a concentration of 20 μM
(DMSO<1%) in tissue culture medium (DMEMwith
10% FBS, 1% L-Glutamine, 1% penicillin-streptomy-
cin), then incubated with the transfected cells for four
hours at 37 °C, 5%CO2. 20 μMcompound concentra-
tion was selected as an appropriate concentration for
assay development and screening. Following incuba-
tion, the cells were detached from the plate by gentle
pipetting and centrifuged for 5 min at 1000 rpm.
Culture medium was removed by pipetting and the
cell pellet re-suspended in FACS buffer (PBS+2%
FBS) to wash off unbound compound. The cells were
centrifuged, as above, and the wash buffer removed.
The cells were then re-suspended in FACS buffer and
transferred to 5 ml FACS tubes. The tubes were
wrapped in foil and placed on ice until sorting.
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Step 2: FACS sorting
Cells were sorted using a BDFACSAria II system fitted
with a 100 μm nozzle. Data was acquired and
processed using BD FACSDiva Software version 6.1.3.
Cell fluorescence was detected using the APC channel,
using the 640 nm laser at 40 mWatt for E2-Crimson
excitation. The filter used was 670/14 nm detecting
fluorescence emission of E2-Crimson in the
663–677 nm range. Cells were sorted and collected
into four cell populations defined by fluorescence
intensity, forward (FSC) and side scatter (SSC) gating
was used to exclude dead cells and only live cells were
collected. Cells were collected in 5 ml FACS tubes
containing 1 ml of DMEM with 10% FBS, 1% L-
Glutamine and 1% penicillin-streptomycin. Each
population of cells was centrifuged at 1000 rpm for
5 min. Medium was removed and the cell pellet re-
suspended in 20 mMHEPES, pH 7.0. The suspension
was briefly sonicated to lyse the cells before centrifuga-
tion, as before, to pellet cell debris. The lysate (super-
natant) was transferred to LC-MS vials and stored at
−20 °Cprior toMS analysis.
Step 3: Mass spectrometry detection of compounds in cell
lysates
Instrumentation
This method was previously described by us [17]. The
chromatographic system used was a TurboFlowTM
TLX Aria-1 system (Thermo Fisher Scientific, Hemel
Hempstead, UK), consisting of two Allegros pumps
defined as the loading and eluting pumps, two valve-
switching modules and a CTC liquid autosampler.
The detection was carried out using a TSQ Quantum
Discovery triple quadrupole mass spectrometer
(Thermo Fisher Scientific,HemelHempstead, UK).
Chromatography and mass spectrometry parameter
optimisation
Samples were subject to online-extraction using a
TurboFlowTM TLX Aria-1 system operated in focus
mode. 10 μl injection of the cell lysate was loaded
directly onto a C18PXL (50×0.5 mm, ThermoFisher
Scientific, Hemel Hempstead, UK) TurboFlowTM
column at a high flow rate, causing the proteinaceous
material to flow to waste. A series of valve switches led
to the elution of the extracted sample from the
TurboFlowTM column directly onto the analytical
column. Solvent A was water with 0.1% formic acid,
Solvent B was methanol with 0.1% formic acid and
Solvent C was 45:45:10 acetonitrile:isopropanol:
acetone.
Following TurboFlowTM extraction, the analytes
were subsequently separated on a reverse phase T3
Atlantis (2.1×150 mm, 3 μm, Waters, Manchester,
UK) analytical column, protected by a Kinetex Krud-
Katcher® (Phenomenex, Macclesfield, UK). The ana-
lytical column was maintained at 5 °C using a column
chiller.
The online TurboFlow system Aria-1 was directly
connected to a Quantum Discovery triple quadrupole
mass spectrometer, operated in electrospray ion mode
with polarity switching for positive and negative ion
monitoring. The source temperature was 300 °C, the
spray voltage 3 kV and the skimmer offset was 12 V.
Argon, the collision gas in Q2, had a pressure of
1.5 mTorr. Automated tune settings were used to
achieve the maximum ion signal for each analyte for
initial validation experiments, optimising on tube lens
voltage, parent to product transitions and collision
energy for each transition. A quantifier and qualifier
ion was determined for each analyte. By monitoring
for quantifier and qualifier ions this adds additional
specificity to the assay. Acceptable quantifier: qualifier
peak area ratios in biological samples were considered
to be those that fell within 20% of the average ratio
seen in standards. By applying tune settings, a peak
area could be generated for each compound. For
pooled compound screening, tune settings were not
used. Samples were subject to a full MS scan with the
molecular weight detection range set at 250–465 (Dal-
tons). Peaks detected in this initial scan were then
identified by molecular weight and checked versus
theirmass-charge ratio.
A scan width ofm/z 0.5, scan time of 0.1 s and unit
resolution on Q1 and Q3 were applied. Data was col-
lected as centroid data to minimise the file sizes. Data
were acquired and processed using Aria 1.3, Xcalibur
1.4 and LCQuan 2.0 SP1 software packages.
Compounds
Three known KMO inhibitors from the patent and
scientific literature [18, 19] and a non-binding com-
pound from the University of Edinburgh Drug Dis-
covery Core compound library were used for assay
development and validation (figure 1). 100 com-
pounds selected from the University of Edinburgh
Drug Discovery Core compound library were pooled
with compounds 1, 2 and 3 (figure 1) and assayed
simultaneously as a mixture to demonstrate multi-
compound screening. The screening library com-
prised of a diverse set of compounds including
compounds inactive at KMO and the three well-
characterised cell permeable KMO inhibitors. Inactive
compounds included those known to be cell perme-
able at other targets. The compound set contained
diverse chemistry with a range of molecular weights
(169–445 Da) and lipophilicities (LogP 0.94–6.1).
KMOactivity assay
All compounds assayed in the compound ‘pool’ were
evaluated for activity against human KMO in a KMO
activity assay. The source of KMO protein for this
assay was lysate generated using the following stable
cell line.
HEK293 (Flp-In-293 which express lacZ-Zeocin,
Life Technologies) cells were stably co-transfected
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with 9 μg of pcDNA5/FRT/V5/HisTOPO DNA and
18 μg of pog44 plasmid. Pog44 expresses Flp recombi-
nase protein, co-transfection of pog44 with the gene of
interest allows targeted integration into the mamma-
lian cell genome within a transcriptionally active
region. Transfection was carried out using Lipofecta-
mine 2000 (Life Technologies) in OPTI-MEM med-
ium (Lonza). Cells were selected for two weeks using
Hygromycin B (Sigma Aldrich) at 100 μg ml−1 to
select for the hygromycin resistance gene contained
within the pcDNA5 vector before positive colonies
were isolated and cultured.
HEK-huKMO cell lysate was analysed for KMO
enzymatic activity by measuring the amount of KYN
converted to 3HK detected using liquid chromato-
graphy-mass spectrometry (LC-MS/MS) following
incubation with the compounds screened in the TAPS
assay using a method we described previously [17].
Compounds were tested in a one compound per well
format in this assay. Briefly, lysate containing 200 μg
total protein was incubated with 4 mMMgCl2, 1 mM
NADPH and 200 μM L-Kynurenine in 20 mM
HEPES, pH 7.0 for two hours at 37 °C with gentle
shaking at 250 rpm in a total assay volume of 100 μl.
Samples were added to 500 μl acetonitrile (containing
25 μg ml−1 of internal standard, d5-TRP) to terminate
activity, followed by centrifugation at 4000 rpm for
20 min to pellet the precipitate. The supernatant frac-
tion was dried under nitrogen, and the residue re-sus-
pended in 30:70 methanol:water with 0.1% formic
acid ready for LC-MS/MSanalysis.
LC-MS analysis was carried out using the TSQ
Quantum Discovery triple quadrupole mass spectro-
meter (Thermo Fisher Scientific, Hemel Hempstead,
UK) using a pentafluorophenyl (PFP) fused pore col-
umn (Waters), at 40 °C. The injection volume was
10 μl and the flow rate was 500 μl min−1. The method
had a run time of 4 min and d5 Tryptophan was used
as an internal standard. Qualifier and quantifier peaks
were identified for 3HK and for d5 Tryptophan. Data
was acquired and processed using Xcalibur 1.4 and LC
Quan 2.0 SP1 software packages.
Cell staining
HEK293 cells were transiently transfected and sorted
by FACS as described above. A sample of cells from
each sorted population were plated in transparent 96
well plates (Whatman) and incubated overnight at
37 °C, 5% CO2. Medium was aspirated from the cells
the following day and the cells gently rinsed with PBS+
Figure 1.The structures and activities of compounds used to validate the cellular TAPSmethod. CAS numbers and literature reported
activities for rat KMOenzyme are shown for Cpds 1–4 alongside the IC50 values generated by us previously in aKMOactivity assay
against human enzyme [17].
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(PBS containing 1 mM Ca2+ and 0.5 mM MgCl2).
Wheat germ agglutinin-AlexaFluor488 conjugate was
used at a concentration of 5 μg ml−1 to stain the cell
membranes by incubation for 10 min at 37 °C. The
stain was removed and the cells rinsed twice with
PBS+. The cells were then fixed by 10 min incubation
in 3.7% formaldehyde diluted in PBS+. After removal
of the fixative, cells were thoroughly rinsed three times
by 5 min incubation in PBS+. To permeabilise the
cells, 0.1%Triton-X 100 in PBSwas added for 5 min at
room temperature. Cells were washed a further three
times before incubation with 300 nMDAPI in PBS for
5 min at room temperature in the dark to allow
nuclear staining. Cells were washed a final three times
in PBS. The cells were imaged using theOperaTMHigh
Content screening system. E2-Crimson-huKMO
fluorescence was detected using the 640 nm laser
(2000 μW, 280 ms), nuclear (DAPI) staining was
detected using the UV light source (365 nm excitation,
emission filter 450/50, 40 ms) and the 488 nm laser
(1250 μW, 40 ms) was used to detect the cell mem-
brane stain (wheat germ agglutinin-Alexa488
conjugate).
Results
Selection and validation of KMO inhibitors
Three known inhibitors of KMO, with nanomolar to
micromolar affinity [18, 19], and one structurally
related, negative control compound (figure 1) were
selected for development and validation of the TAPS
assay. The activity of these inhibitors was verified by us
previously against human KMO [17] in the enzyme
activity assay described in the methods section and the
IC50 values generated were in a similar range to
literature values reported against rat KMO enzyme for
compounds 1–3 (figure 1). Compound 4 was con-
firmed to be inactive in the activity assay (figure 1).
Cellular E2-crimsonfluorescence correlateswith
KMOactivity
KMO was detectable in the cellular matrix as a far red
fluorescent conjugate by fusionwith E2-Crimson [20].
A broad range of cellular fluorescence intensities
resulting from transient expression of fluorescent
KMO were detected and sorted by FACS to generate
the cell populations forMS analysis. Confocal imaging
of cells from the sorted populations was used as a
parallel method to confirm KMO expression
(figures 2(a), (b)). Sorted cell populations, when lysed
and assayed for KMO enzymatic activity, showed good
correlation between increased fluorescence intensity
and KMO enzyme activity (figure 2(c)). Therefore,
cellular E2-Crimson fluorescence reliably indicated
KMOexpression and functionality.
Intracellular target-binding of KMO inhibitors is
detected in the TAPS assay
LC-MS/MS detection of the KMO inhibitors (Cpds
1–3) in cell population lysates in the TAPS assay
correlated strongly and in a concentration dependent
way with levels of target expression, indicating specific
inhibitor affinity for KMO (figure 3(a)). MS detection
of inactive compound 4 demonstrated very low and
approximately equal signal in all cell population
lysates, indicating little or no specific affinity for KMO
(figure 3(a)). Furthermore, LC-MS/MS compound
detection in fluorescent KMO-positive samples
reflected the half maximal inhibitory concentrations
generated in the KMO activity assay (figure 3(b)). This
suggests that the compounds are demonstrating
intracellular affinity for KMO and not its E2-Crimson
fusion partner. These results show that the TAPS assay
protocol can be utilised to identify cell permeable
compoundswith specific binding affinity for KMO.
Intracellular target-binding compounds can be
detected fromapooled compoundmixture
To test the multiplexing potential of the technique,
103 compounds at a final concentration of 20 μM
each, including validation compounds 1, 2 and 3, were
assayed simultaneously in one cellular incubationmix.
Compounds 1, 2 and 3were the only compounds to be
detected solely in the high fluorescence-KMO positive
sample indicating that the TAPS assay can be applied
for testing medium sized compound collections
(figure 3(b)). This screen also identified compounds
with equal detection across all samples indicating non-
specific binding or high cellular permeability. These
results were verified by compound testing in the KMO
activity assay (figure 3(b)). Binding specificity was
shown to correlate with inhibitory activity in the
activity assay confirming reliable identification of hit
and false positive compounds in the TAPS assay.
Discussion
Monitoring of drug-target engagement inside cells
represents a challenge in the early drug discovery
process. Molina et al [9] described the CETSA which
addresses intracellular drug-target engagement but
also confirmed that the method is unsuitable for
inhomogenous proteins or those which do not aggre-
gate upon unfolding of the ligand-binding domain.
Thus there is a need for methods which are applicable
to difficult target proteins and for simultaneously
testing large sets of test compounds for the evaluation
of drug-to-protein binding inside cells. The TAPS
assay compares compound detection in cells which
demonstrate variable expression of target protein.
Utilising known inhibitors of our selected target
enzyme, it was shown that the specific affinity of these
compounds for the target could be indicated by
comparing compound accumulation in cells with
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over-expressed levels of target protein compared to
non-specific accumulation in normal cells. Com-
pounds with equivalent accumulation in overexpres-
sing cells compared to untransfected cells are
identified as non-specific binders and excluded.
Because only cell permeable target specific binders are
comparatively enriched in overexpressing cells, rela-
tive compound binding affinity and cellular perme-
ability can be revealed simultaneously by MS analysis.
Key control experiments include testing the com-
pound(s) of interest in incubation with variably and
transiently transfected cells, fluorescent protein only
transfected cells, and, if needed, relevant target
mutants and related proteins. Where transient expres-
sion of a target protein cannot be achieved, a similar
analysis can be provided utilising stably transfected
cells verses non-transfected cells. The caveat for either
iteration of the assay is the requirement for expression
of fluorescently-tagged target protein. Also, themicro-
plate format applied to assay a particular target, i.e. the
throughput which can be achieved, depends upon the
level of protein expression since the quantity of bound
compound detected correlates with the quantity of
protein present. Endogenous expression of the target
protein should be considered when selecting cells for
TAPS analysis.
We selected KMO, a challenging but increasingly
important target enzyme, for development of this
assay. Protein targets, like KMO, which require com-
plexation with cellular interactome proteins or chemi-
cal co-factors pose difficulties for in vitro biochemical
preparation and testing. To overcome these specific
challenges we omitted enzyme purification steps and
assayed target enzymes directly in mammalian cells in
the presence of co-factors and intracellular binding
proteins required for enzyme functionality. HEK293
Figure 2.Expression of functional hKMOand compound screening in the TAPS assay. (a)Transient transfection ofHEK293 cells with
E2-Crimson-huKMOgenerates populations of variably transfected cells, the histogram shows the distribution offluorescence
intensity in the transfected cells and the population gates applied for cell sorting, (b) cellular staining images obtained using the
OperaTMHighContent Screening system show variable expression of E2-Crimson in each sorted population (shown in red). E2-
Crimson-huKMO fluorescencewas detected using 640 nm laser excitation (2000 μW, 280 ms), DAPI staining (shown in blue)was
detected using theUV light source (365 nmexcitation, emissionfilter 450/50, 40 ms) and the 488 nm laser (1250 μW, 40 ms)was
used for exciation of the cellmembrane stain (shown in green, wheat germ agglutinin-Alexa488 conjugate). (c) 3-HKproduced per
cell in each sorted cell population lysate after incubationwith 200 μMkynurenine substrate for 2 h correlates withfluorescence
intensity in the cell. Data are representative of two independent experiments.
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cells were selected for analysis of KMO in the TAPS
assay. Whilst KMO is expressed by kidney cells,
HEK293 cells do not exhibit detectable KMO activity
[20]. Thus, HEK293 cells provide a physiologically
relevant matrix for the assay but the outcome of the
analysis was unlikely to be impacted by endogenous
KMO. More generically for all targets, if endogenous
expression of the target is abundant in the cell type
used, we acknowledge that this could have the poten-
tial to confound the results. In those circumstances, it
would be possible to select another cell-type, this may
not be necessary given that the important measure of
compound-target binding is the relative enrichment
of compound in cells expressing fluorescent target
compared to non-fluorescent. Therefore, as long as
the unknown compounds are tested in excess, as we
have done, binding should be apparent. Successful
application of this method to membrane proteins
indicates suitability for assay of other challenging tar-
gets such as full length protein–protein interaction
partners or proteins which are only stable in the pre-
sence of nucleic acids or lipids.
KMO was detectable in the cellular matrix follow-
ing fusion with E2-Crimson [21]. FACS and confocal
imaging experiments confirmed that cellular E2-
Crimson fluorescence reliably indicated KMO expres-
sion and functionality. Transient transfection of cells
inevitably resulted in variable expression of fluor-
escent target protein allowing extraction of a negative
control sample and a KMO-positive sample from the
same cellular drug incubation. This step in the assay
facilitates discrimination between compounds
demonstrating non-specific cellular component bind-
ing in all cells from compounds exhibiting specific
binding affinity in cells expressing higher concentra-
tions of target protein. Detection of the known KMO
Figure 3. (a)The quantity of compound detected byMS for knownKMO inhibitors (compounds 1–3), represented here as the total
peak area detected in a sorted cell sample divided by the number of cells in the population to give compound peak area per cell,
increases with the expression offluorescent target protein detected by FACS. The quantities of validation compounds 1–4 detected by
MS in the TAPS assay also correlate with the inhibitory activities of each compound. Data are representative of two independent
experiments. (b)Plot showing the correlation between inhibitory activity determined in the KMOactivity assay and the quantity of
compound detected in cells in the ‘high’fluorescence/KMOpopulation in the TAPS assay for the compounds in the pooled screen.
Each • represents one compound in the screen. Cpds 1–3 are indicated by their IC50 values. Data are representative of one independent
experiment.
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inhibitors in the TAPS assay correlated in a concentra-
tion dependent manner with levels of target expres-
sion, indicating specific affinity for KMO. The known
inactive compound demonstrated an invariable signal
regardless of target expression, indicating little or no
specific affinity for KMObut also no unspecific or pro-
miscuous binding cellular proteins. Detection of these
compounds in the TAPS assay reflected the half max-
imal inhibitory concentrations generated using the
KMO activity assay. Differences in the apparent intra-
cellular binding curves, particularly of the two com-
pounds with similar IC50s are most likely connected to
cellular uptake, unspecific binding events or com-
pound-specific ionisation duringMS readout.
As a next step in the TAPS assay development we
tested the multiplexing potential of the technique. 103
compounds were assayed simultaneously in one cel-
lular incubation mix. Detection of the three known
KMO inhibitors in the high fluorescence-KMO posi-
tive sample suggested suitability of TAPS for testing
medium sized compound collections. The screen dis-
criminated compounds showing non-specific binding
or high cellular permeability from knownKMO-bind-
ing compounds with results successfully validated in
theKMOactivity assay. By comparing the output from
each method we were able to confirm reliable identifi-
cation of hit and false positive compounds in the TAPS
assay.
The TAPS method is a multi-parameter tool that
delivers on several aspects of compound characterisa-
tion. Whilst target binding and cellular permeability is
assessed for compounds detected by MS readout,
compounds demonstrating cellular cytotoxicity are
excluded at the FACS step of the assay. FACS analysis
was programmed to incorporate only live healthy cells,
by utilising forward scatter and side scatter gating to
eliminate dead cells, meaning that compounds with
undesirable cytotoxicity potential are eradicated from
the screen. Should further activity data be required for
compounds tested by TAPS, lysates resulting from
FACS analysis can be directly applied to secondary
activity assays, such as the enzyme activity assay
demonstrated here. In an alternative assay configura-
tion, a cellular permeabilisation step, like automated
optoinjection using LEAP, can successfully be incor-
porated in the TAPS assay to enable utilisation of the
TAPS method for compounds which are not required
to permeate the cells (data not shown).
We currently consider that the TAPS assay could
be quickly and smoothly integrated into biochemical
and biophysical affinity selection, enzymatic and phe-
notypic screening workflows to prove that any hit
compounds engage with the target under invest-
igation. In addition, the TAPS assay might also offer
significant value in its potential for medium through-
put, multiplexed screening of experimentally challen-
ging protein targets, like intracellular membrane
proteins, which are otherwise hindered by a lack
of a suitable screening technique. Development and
application of the TAPS assay for screening com-
pounds against KMO inside cells indicates that this
technique is suitable for targeting other challenging
proteins. Besides screening intracellular membrane
proteins we also consider TAPS to be the method of
choice for intracellular affinity selection assays for lar-
ger scale multi-protein complexes containing targe-
table protein–protein interactions or not easily
purifiable targets, such as full length kinases. The
excellent quantification possibility of both, protein
concentration via fluorescent protein intensity, as well
as compound concentration via MS will also allow
addressing so far unresolved questions about inhibitor
to protein stoichiometry in disease versus healthy cells.
An other further iteration of this method will utilise
primary tissue cultures. This will enable optimal, phy-
siologically relevant host cell selection tailored to spe-
cific target proteins. Thismay prove especially relevant
in cancer therapy since the assay could be applied to
drug screening in biopsied tumour cells.
Conclusion
In conclusion, we report a novel cellular screening
technique for assessing intracellular drug-target
engagement. TAPS is a dual parameter technique
which is multiplexed with respect to compound and,
in a single assay method, enables identification of
compounds which are cell permeable, have low
cytotoxicity and demonstrate specific affinity for the
target protein in a physiologically relevant environ-
ment. We demonstrated the potential for the TAPS
assay by successful screening of the poorly soluble and
challenging protein human, KMO.With target valida-
tion and target engagement representing two key
limiting factors within the revived importance of
phenotypic and high-content screening, we present
this solution, which uses off-the-shelf equipment
accessible to many scientists in the field. With equally
high value, this straightforward workflow will allow
direct screening of new targets by affinity selection that
until now have only been accessible by indirect
detection. We regard important potential targets to
include intercompartmental membrane proteins
including nuclear envelope transmembrane proteins
known to be involved inmany cancers. Drug discovery
processes are often hindered by issues encountered
during preparation of difficult target proteins. Screen-
ing of target proteins in a physiologically relevant
environment using this method may present a solu-
tion, as demonstrated by successful screening of the
poorly soluble and challenging protein humanKMO.
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